Erasca, Inc (ERAS) releases slides on phase 1 data for RAS cancer drug ERAS-0015

April 27, 2026 4:49 PM

Erasca, Inc (NASDAQ: ERAS) disclosed:On April 27, 2026, Erasca, Inc. (the “Company”) announced positive preliminary Phase 1 dose escalation data ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found